{
    "clinical_study": {
        "@rank": "142770", 
        "acronym": "BEVIAC", 
        "brief_summary": {
            "textblock": "The purpose of the study is to assessed the efficiency of treatment based on the objective\n      response rate (RECIST 1.1)"
        }, 
        "brief_title": "Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Liver metastases of colon cancer or rectal predominant (histological evidence\n             obtained on the primary tumor or liver metastases)\n\n               -  Isolated (no extra-hepatic metastasis, primary tumor resected)\n\n               -  No access to curative hepatectomy (R0 resection foreseeable or not leaving less\n                  than 30% residual non-tumor liver normally vascularized), or requiring complex\n                  hepatectomy, very large (5 or more segments) and / or risked (class II CPP)\n\n               -  which at least one measurable by RECIST (>2 cm, or >1 cm if Computed tomography\n                  (CT) spiraled)\n\n               -  Or extra-hepatic disease of small size potentially accessible to a resection\n                  (one or two lung metastases, lymphadenopathy localized accessible to curative\n                  resection)\n\n               -  colon or rectal primary tumor : resected or asymptomatic\n\n          -  Progression after first line chemotherapy to treat the metastatic disease, all types\n             of treatment allowed except intra-arterial Bevacizumab\n\n          -  Age >18 years <75 years\n\n          -  Performance status WHO 0 or 1\n\n          -  Life expectancy >3 months\n\n          -  Bilirubin <1.5 times the upper limit of normal (N), ASAT and ALAT <5N, creatinine\n             <1.5 N neutrophils  >1.5 x 10^9/L, platelets \u2265100 x 10^9/L, hemoglobin >9g/dL.\n             Patients may be included even if they were transfused\n\n          -  CT (or MRI) reference for the measurement of metastases performed within 28 days\n             before the first treatment cycle\n\n          -  Information of the patient or legal representative signing the informed consent\n\n          -  Affiliated to a social security system\n\n        Exclusion Criteria:\n\n          -  Symptomatic colon or rectal primary tumor (sub-occlusion, significant hemorrhage,\n             major rectal syndrome)\n\n          -  Extra-hepatic metastases other than small size disease potentially accessible  after\n             resection\n\n          -  Grade 3-4 allergy to one of the treatment compounds\n\n          -  Two lines of prior chemotherapy. One line is allowed for metastatic disease but must\n             have been started more than 6 months after completion of adjuvant treatment.\n\n          -  Participation during or within 30 days before study to another therapeutic trial with\n             an experimental molecule\n\n          -  Concomitant cancer systemic treatment using immunotherapy, chemotherapy or hormone\n\n          -  Symptomatic CHD or myocardial infarction within 6 months prior entry into the study,\n             cardiac arrhythmia uncontrolled despite treatment\n\n          -  Uncontrolled hypertension (blood pressure >150/100 mm Hg despite hypertensive\n             treatment)\n\n          -  Heart Failure >Grade II of the New York Heart Association (NYHA) (class\n             II-III-IV)severe renal failure\n\n          -  History and / or presence of bleeding disorders and/or thrombotic <6 months\n\n          -  Uncontrolled Serious illness, uncontrolled active infection or other serious\n             underlying condition which may prevent the patient to receive treatment\n\n          -  Pregnancy (or positive pregnancy test at baseline), lactation or no contraception\n             effective for men or women of childbearing age\n\n          -  Occlusion or sub-bowel obstruction or history of inflammatory bowel disease\n\n          -  Other cancer within 5 years prior to entry into the trial or concomitant (except in\n             situ cancer of the cervix or skin basal-cell carcinoma  properly treated)\n\n          -  Legal inability  (persons deprived of liberty or under guardianship)\n\n          -  Inability to sign the consent or submit to medical test for geographical, social or\n             psychological reasons."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677884", 
            "org_study_id": "2011-005559-15", 
            "secondary_id": "CSET 2011/1827"
        }, 
        "intervention": [
            {
                "description": "Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "Every 3 weeks: 2000 mg/m\u00b2/d in 2 times/d from D1 to D4", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "Every 3 weeks: 200mg/m\u00b2 in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m\u00b2 in 2h IV at D1 (if irinotecan in first line)", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Capecitabine", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 19, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Institut Gustave Roussy"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy", 
        "other_outcome": {
            "measure": "Total area under the curve of contrast-enhanced liver ultrasound", 
            "safety_issue": "No", 
            "time_frame": "Assessed up in baseline, D7, D14, W4, W7 and every 9 weeks up to progression"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Michel Ducreux, MD-PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Efficiency of treatment based on objective response rate", 
            "safety_issue": "No", 
            "time_frame": "Every 9 weeks from the start to tumoral progression"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Treatment toxicity based on NCI-CTC v4.0", 
                "safety_issue": "No", 
                "time_frame": "Every 3 weeks from the start to tumoral progression or toxicity preventing further processing"
            }, 
            {
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Every 9 weeks form the start to tumoral progression"
            }, 
            {
                "measure": "Hepatic metastasis resection rate", 
                "safety_issue": "No", 
                "time_frame": "Assessed up 6 months after the end of treatment"
            }
        ], 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }
}